Innate Pharma announces updated results from SAR443579/IPH6101

Innate Pharma (IPHA) announced that updated efficacy and safety results from the dose-escalation part of the Phase 1/2 study with SAR443579/IPH6101, an investigational CD123 targeting NKp46/CD16-based Natural Killer Cell Engager, or NKCE, from a joint research collaboration between Innate Pharma and Sanofi (SNY) and Anket platform lead asset, were shared in an oral presentation at the European Hematology Association 2024 Congress in Madrid, Spain on Sunday. The study, led by Sanofi, tests SAR’579 as a monotherapy for the treatment of blood cancers with high unmet needs, including relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia and high-risk myelodysplasia. SAR’579 has FDA Fast Track Designation for the treatment of acute myeloid leukemia. Fifty-nine patients across 11 dose levels were treated. Patients had received a median of 2 prior lines of treatment. A maximum response rate was observed at a final target dose of 1 mg/kg every week with 5 AML patients achieving a CR. The median treatment duration was 7.9 weeks, with durable CR observed in 3 patients with 2 remaining on maintenance therapy as of the data cutoff. SAR’579 was well tolerated up to doses of 6 mg/kg every week. These data will form the basis for selection of recommended doses for development in the Phase 2 portion of the trial.